Updated:
GH Research
GH Research was founded in 2018 in Dublin, Ireland, by Theis Terwey with backing from life-science venture investors before its June 2021 IPO on Nasdaq...
GH Research
GH Research was founded in 2018 in Dublin, Ireland, by Theis Terwey with backing from life-science venture investors before its June 2021 IPO on Nasdaq raised approximately $160 million. The company does not manage third-party capital as a fund; it operates as a publicly traded biotech with a single-asset pipeline built around an inhalable formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a short-acting psychedelic. Terwey has structured the firm as a lean Irish-incorporated entity conducting clinical trials in Europe, a regulatory pathway designed to generate data that supports eventual FDA and EMA approvals. The company's entire research program targets treatment-resistant depression (TRD) through a proprietary aerosol delivery system. The lead candidate, GH001, completed a Phase 2b trial in 2024 in seven European countries — the largest controlled study of 5-MeO-DMT to date in a major depressive disorder population (per public record). GH Research also maintains a backup program, GH002, an injectable mebufotenin formulation that entered Phase 1 in 2023, and a preclinical candidate, GH003, aimed at mental health indications beyond depression. The firm has not partnered with any large pharmaceutical company, keeping full control of regulatory filings and commercialization rights across all major markets including the United States, the European Union, and the United Kingdom. As a Nasdaq-listed entity, GH Research reports cash reserves and R&D expenditure rather than assets under management. The company ended 2024 with approximately $160 million in cash, which management estimated funds operations into 2026. Dr. Dermot O'Toole, a seasoned Irish pharmaceutical executive, serves as Chairman. Terwey and his scientific team operate from Dublin, with clinical operations concentrated in European trial sites in countries including the Netherlands, Germany, and the Czech Republic. In September 2024, the company reported positive topline Phase 2b data showing statistically significant reductions in depression severity scores across all dose groups at day 7, sending the stock up in after-hours trading. GH Research occupies a unique corner of the psychedelic medicine landscape: nearly every competitor in the TRD space — Compass Pathways, Cybin, atai Life Sciences — works with psilocybin or longer-duration molecules requiring multi-hour supervised sessions. GH Research's 5-MeO-DMT approach compresses the psychedelic experience to roughly 20 minutes of peak drug effect, potentially enabling a radically simpler clinical workflow and lower treatment-site burden. Whether this brevity translates to durable efficacy equivalent to longer-acting compounds remains the binary risk that will be tested in Phase 3 trials expected to begin in 2025.
General information
Firm type
Asset Manager
Year founded
2018
AUM
Undisclosed
Location
Region
Europe
Country
Ireland
City
Dublin
Corporate office
Dublin, Ireland
Principals
Theis Terwey
Chief Executive Officer and Co-Founder
Dr. Dermot O'Toole
Chairman
Sector focus
Frequently asked questions
What is GH Research's sole therapeutic candidate, and why is it structurally different from other psychedelic assets?
GH001 is a proprietary inhalable formulation of 5-MeO-DMT, a short-acting psychedelic that produces a peak drug experience lasting approximately 20 minutes — far shorter than the 6-to-8-hour sessions required by psilocybin-based competitors. The company claims its aerosol delivery device produces rapid onset and a consistent pharmacokinetic profile, which could allow a single-day outpatient treatment model for treatment-resistant depression. The molecule itself is not novel, but the combination of delivery route and clinical indication is.
Who runs investment decisions at GH Research?
GH Research is a publicly traded company, not an investment vehicle. Capital allocation decisions — primarily R&D spending, clinical trial design, and cash management — are made by CEO and co-founder Theis Terwey with oversight from Chairman Dr. Dermot O'Toole and the board of directors. The company raised $160 million in its June 2021 Nasdaq IPO and has not disclosed plans to raise additional equity through a follow-on offering.
How does GH Research differ from Compass Pathways or other listed psychedelic companies?
The key structural difference is the molecule's duration. Compass Pathways uses COMP360, a synthetic psilocybin requiring a 6-to-8-hour supervised session in a dedicated therapy room. GH Research's 5-MeO-DMT approach compresses the altered state to roughly 20 minutes, which the company argues will reduce site infrastructure costs and allow a higher patient throughput per treatment center. GH Research also operates almost entirely in Europe for clinical development, whereas Compass runs global trials.
What is GH Research's cash position and runway?
The company reported holding approximately $160 million in cash, cash equivalents, and marketable securities as of year-end 2024 (per public record). Management has guided that this balance funds planned operations into 2026, covering the anticipated start of Phase 3 trials for GH001 in 2025 and continued preclinical work on backup candidates.
What backup programs does GH Research have if GH001 fails?
GH002 is an injectable formulation of mebufotenin (5-MeO-DMT's primary metabolite) that completed Phase 1 healthy-volunteer trials in 2023. The company also lists GH003, a preclinical candidate targeting mental health indications outside of depressive disorders. Neither program has received the level of funding or disclosed detail that GH001 has, and both are meaningfully earlier in the development cycle.
Is GH Research an investment fund or asset manager?
No. GH Research is a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker GHRS. It does not manage outside capital, raise funds, or operate a family office structure. The company develops drug candidates with the intent of seeking regulatory approval and eventual commercialization.
What is GH Research's regulatory strategy across major markets?
The company has run its Phase 2b trial across seven European countries and maintains a European-first clinical development strategy, using data from these trials to inform eventual applications to both the EMA and FDA. GH Research owns global commercial rights to its pipeline and has not licensed or partnered any territory to a larger pharmaceutical company as of early 2025.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: